Today: 16 July 2026
Rackspace (RXT) stock back in play as Palantir AI deal meets earnings week

Rackspace (RXT) stock back in play as Palantir AI deal meets earnings week

New York, Feb 23, 2026, 05:15 EST — Premarket

  • Rackspace looked set to open at about $1.68, right around where it finished on Friday.
  • Rackspace shares have seesawed since the company announced its AI tie-up with Palantir.
  • Attention shifts to Rackspace’s Feb. 26 results, where investors want specifics on how revenue was affected.

Rackspace Technology was trading near $1.68 ahead of the open Monday, almost flat versus Friday’s close. Last week’s surge still lingered.

The cloud outfit out of San Antonio has been on a tear, catching traders’ attention after announcing a collaboration with Palantir Technologies. The partnership is aimed at helping clients roll out Palantir’s Foundry and Artificial Intelligence Platform. “Organizations need AI that works in production, not just in demos,” said CEO Gajen Kandiah. Shares, stuck near 42 cents at the week’s open, soared to $1.68 by Friday’s close. San Antonio Express-News

Timing’s key here: Rackspace heads into earnings week with a chart that’s looking for some confirmation. The company’s set to report its fourth-quarter 2025 numbers at 8 a.m. ET on Feb. 26, then Kandiah and CFO Mark Marino get on the conference call at 8:30 a.m. ET.

Rackspace is touting its partnership with Palantir as a route for customers to push AI projects straight into production, not just run more pilots. The company says its “governed operating model” comes with managed security and compliance, so clients get built-in guardrails. Rackspace also outlined plans to host Palantir’s software on its Private Cloud and in UK sovereign data centers, targeting customers bound by data sovereignty laws. “Palantir AIP is taking completion timelines from years to days,” Palantir’s U.S. commercial chief Sameer Kirtane said in the announcement. Rackspace Technology

Rackspace shares surged 36.7% Friday, closing sharply higher after ranging from $1.30 to $2.08 throughout the session, according to Markets Insider data.

Palantir was flat in early action, with shares holding at $135.24.

With Rackspace, the main concern isn’t just the headline deal. Traders want to know how fast the Palantir partnership can actually produce signed contracts and steady managed-services income. There’s also the issue of whether the company will have to front-load spending to hire and operate teams for those deployments.

The usual unwind risk hasn’t gone away. If management skips the numbers on the partnership, or hints that “interest” is not turning into revenue as quickly as hoped, a rally into results can just as easily flip into a vacuum.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Housing Market Dips as High Rates, Prices Hit Buyers and Builders
    July 16, 2026, 2:21 PM EDT. Pending home sales fell 5.4% in June. Buyer interest dropped with 30-year fixed mortgage rates at 6.64%, the highest in almost a year. The National Association of Realtors said all-time high home prices with higher borrowing costs are reducing demand. First-time buyers face the most difficulty. At the same time, homebuilder sentiment hit its lowest in nearly a year. Builders blame higher construction costs, hard-to-find workers, and affordability. In July, almost 37% of builders cut prices. Over 60% used sales incentives. The market stays tough as home buying and building costs rise, even with new laws aimed at making development easier.
Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Previous Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop